The district of columbia clinical trials unit (DC CTU)
Active Cooperative Agreement Awarded Last action
- Award ID
- UM1AI154466
- Recipient
-
George Washington University (The) UEI ECR5E2LU5BL6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $39,346,241
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 84% complete
- Funding
-
- $37,922,705.00 Federal
- $1,423,536.00 Non-federal
- Place of performance
- Washington, DC 20037, USA
Award details come from USAspending.gov.
Description
- Abstract
- The district of columbia clinical trials unit (DC CTU) will conduct clinical trials for persons with and at risk for HIV in DC, where 1.8% of the overall population and 2.7% of the african-american population are living with HIV. The DC CTU will unite two existing, high-performing daids/niaid clinical research sites (CRS), the whitman-walker health CRS and the george washington university CRS, in a new CTU, participating in the HIV/aids adult therapeutics and HIV prevention clinical trials networks. Our innovative and geographically- focused DC CTU will ensure exemplary clinical trials management, recruitment, and retention of a diverse sample of participants, with a community engagement strategy built on existing partnerships and good participatory practices. The DC CTU will achieve four specific aims: 1) provide scientific leadership and administrative infrastructure to allow high-quality conduct of therapeutic and prevention studies at two established crss; 2) implement best practices to ensure continued high recruitment and retention rates; participant safety; and laboratory, pharmacy, data, and regulatory excellence; 3) actively engage with the local community to ensure optimal enrollment of diverse participants from within and beyond clinic settings using good participatory practices; and 4) capitalize on the resources available from the DC cfar and DC cohort to engage senior investigators, mentor investigators in clinical trials conduct, and access a broad array of services to address NIH and network scientific and programmatic priorities. The DC CTU will engage participants who can benefit from innovative clinical trials while we contribute to high-quality participatory research that will eventually end the HIV epidemic.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $21,103 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $872,805 | |
| Amendment | $872,805 | |
| Amendment | $872,805 | |
| Amendment | $792,461 | |
| Amendment | $792,461 | |
| Amendment | $792,461 | |
| Amendment | $792,461 | |
| Amendment | $1,141,934 | |
| Amendment | $1,141,934 | |
| Amendment | $1,141,934 | |
| Amendment | $1,141,934 | |
| Amendment | $1,141,934 | |
| Amendment | $776,122 | |
| Amendment | $776,122 | |
| Amendment | $776,122 | |
| Amendment | $776,122 | |
| Amendment | $776,122 | |
| Amendment | $776,122 | |
| Amendment | $66,607 | |
| Amendment | $66,607 | |
| Amendment | $66,607 | |
| Amendment | $66,607 | |
| Amendment | $638,723 | |
| Amendment | $66,607 | |
| Amendment | $638,723 | |
| Amendment | $679,092 | |
| Amendment | $679,092 | |
| Amendment | $679,092 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $679,094 | |
| Amendment | $679,094 | |
| Amendment | $335,600 | |
| Amendment | $679,094 | |
| Amendment | $679,094 | |
| Amendment | $721,045 | |
| Amendment | $721,045 | |
| Amendment | $721,045 | |
| Amendment | $721,045 | |
| Amendment | $208,550 | |
| Amendment | $208,550 | |
| Amendment | $861,932 | |
| Amendment | $861,932 | |
| Amendment | $208,550 | |
| Amendment | $208,550 |
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Frontier Science & Technology Research Foundation, Inc. | $183,655 | |
| Whitman-Walker Clinic Inc. | $82,858 | |
| Frontier Science & Technology Research Foundation, Inc. | $1,081,807 | |
| Whitman-Walker Institute Inc. | $621,749 | |
| Whitman-Walker Institute Inc. | $294,581 | |
| Whitman-Walker Institute Inc. | $269,693 | |
| Whitman-Walker Institute Inc. | $159,860 | |
| Whitman-Walker Institute Inc. | $269,624 | |
| Whitman-Walker Institute Inc. | $3,571,274 |
Quick answers
Who received award UM1AI154466?
UM1AI154466 was awarded to George Washington University (The) by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 1, 2020.
How much is award UM1AI154466 worth?
$39,346,241 has been obligated on UM1AI154466: $37,922,705 in federal funding and $1,423,536 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award